


## Dusquetide TFA

|                             |  |
|-----------------------------|--|
| <b>Cat. No.:</b>            | HY-P2076A  |
| <b>Molecular Formula:</b>   | C <sub>27</sub> H <sub>48</sub> F <sub>3</sub> N <sub>9</sub> O <sub>7</sub> |
| <b>Molecular Weight:</b>    | 667.72   |
| <b>Sequence:</b>            | {Arg}{Ile}{Val}{Pro}{Ala}-NH <sub>2</sub>                                    |
| <b>Sequence Shortening:</b> | RIVPA-NH <sub>2</sub>  |
| <b>Target:</b>              | Bacterial  |
| <b>Pathway:</b>             | Anti-infection   |
| <b>Storage:</b>             | Sealed storage, away from moisture and light                                 |
|                             | Powder    -80°C    2 years   |
|                             | -20°C    1 year  |



\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

### BIOLOGICAL ACTIVITY

|                    |   |               |  |         |          |                 |                                |         |  |
|--------------------|---|---------------|--|---------|----------|-----------------|--------------------------------|---------|--|
| <b>Description</b> | Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection <sup>[1]</sup> . DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns  |               |  |         |          |                 |                                |         |  |
| <b>In Vivo</b>     | <p>Dusquetide (SGX942) TFA (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female nude mice (MCF-7 tumor xenografts)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>25 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>I.v.; days 0, 4, 7, 10, and 14</td> </tr> <tr> <td>Result:</td> <td>Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.</td> </tr> </table> | Animal Model: | Female nude mice (MCF-7 tumor xenografts) <sup>[1]</sup> | Dosage: | 25 mg/kg | Administration: | I.v.; days 0, 4, 7, 10, and 14 | Result: | Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation. |
| Animal Model:      | Female nude mice (MCF-7 tumor xenografts) <sup>[1]</sup>  |               |  |         |          |                 |                                |         |  |
| Dosage:            | 25 mg/kg  |               |  |         |          |                 |                                |         |  |
| Administration:    | I.v.; days 0, 4, 7, 10, and 14  |               |  |         |          |                 |                                |         |  |
| Result:            | Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.  |               |  |         |          |                 |                                |         |  |

### REFERENCES

[1]. Kudrimoti M, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115-125.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA